HRS9531 Controls Weight Regain in Obese Subjects

Summary

This is a single-center, double-blinded, randomized, placebo-controlled phase II study to explore the effectiveness, safety and energy balance mechanism of low-frequency continuous subcutaneous injection of HRS9531 to inhibit weight regain in obese non-diabetic and obese diabetic patients

Timeline

Start

2024-01-01

Primary completion

2025-06-30

Completion

2025-12-31

Drugs

Indications